Preoperative Periprosthetic joint infection linked to higher rates of depression: Study

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-02-19 03:30 GMT   |   Update On 2022-02-19 03:30 GMT

Patients undergoing 2-stage exchange for Periprosthetic joint infection (PJI) have a four times higher prevalence of preoperative depressive symptoms than patients undergoing aseptic revision, according to a recent study published in the Arthroplasty Today. Periprosthetic joint infection (PJI) is a devastating complication after total joint arthroplasty. Patients undergoing...

Login or Register to read the full article

Patients undergoing 2-stage exchange for Periprosthetic joint infection (PJI) have a four times higher prevalence of preoperative depressive symptoms than patients undergoing aseptic revision, according to a recent study published in the Arthroplasty Today.

Periprosthetic joint infection (PJI) is a devastating complication after total joint arthroplasty. Patients undergoing revision for PJI may experience psychological distress and symptoms of depression, both of which are linked to poor postoperative outcomes. We, therefore, aim to identify the prevalence of depression and depressive symptoms in patients before treatment for PJI and their link to functional outcomes.

Patients undergoing either debridement with implant retention (DAIR) or 2-stage exchange for PJI with minimum 1-year follow-up were retrospectively reviewed. The 2-stage (n = 37) and single-stage (n = 39) patients that met inclusion criteria were matched based off age (±5 years), gender, and body mass index (±5) to patients undergoing aseptic revisions. Outcomes evaluated included a preoperative diagnosis of clinical depression and preoperative and postoperative Veterans RAND 12 Item Health Survey mental component score and physical component score.

Results of the study are:

Compared to matched controls, the prevalence of depressive symptoms was significantly greater in patients undergoing 2-stage exchange preoperatively (40.5% vs 10.8%, P < .01) but not postoperatively (21.6% vs 10.8%, P = .20). Patients undergoing DAIR with either preoperative depressive symptoms (31.3 vs 40.9, P = .05) or a preoperative diagnosis of depression (27.7 vs 43.1, P < .01) had significantly lower physical component scores postoperatively.

Patients undergoing 2-stage exchange for PJI have a four times higher prevalence of preoperative depressive symptoms than patients undergoing aseptic revision. Patients undergoing DAIR with depression or preoperative depressive symptoms have lower functional scores postoperatively. Orthopaedic surgeon screening of PJI patients with referral for treatment of depression may help improve outcomes postoperatively.

This study demonstrates that the prevalence of depressive symptoms is greater than 40% in patients undergoing 2-stage ex- change arthroplasty. In addition, patients undergoing DAIR with preoperative depressive symptoms or a preoperative diagnosis of depression have a significantly lower improvement in post-operative physical function. Prior literature has established that surgical outcome could be further improved if orthopaedic surgeons appropriately screened patients undergoing arthroplasty for depressive symptoms and referred them to appropriate care preoperatively. Thus, the results of this study may help in- crease awareness of the high prevalence of depressive symptoms in patients undergoing revision for PJI and ensure that this modifiable risk factor is addressed. Further study is required to prospectively evaluate the role of depression as a modifiable risk factor in the treatment of PJI to help improve outcomes postoperatively.

Reference:

Increased Prevalence of Depressive Symptoms in Patients Undergoing Revision for Periprosthetic Joint Infection by Vishal Hegde, et al. published in the Arthroplasty Today.

https://www.arthroplastytoday.org/article/S2352-3441(21)00189-8/fulltext


Tags:    
Article Source : Arthroplasty Today

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News